Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    E011-MEL
Previous Study | Return to List | Next Study

Safety of Intranodal ECI-006 in Melanoma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03394937
Recruitment Status : Terminated (Expiry of study medication)
First Posted : January 9, 2018
Last Update Posted : June 21, 2021
Sponsor:
Information provided by (Responsible Party):
eTheRNA immunotherapies

Brief Summary:

The purpose of this study is to assess the safety and tolerability of cancer immunotherapy ECI-006 and to determine its ability to induce a measurable immune response against the tumor associated antigens.

In Cohort 1, ECI-006 will be administered 5 times by intranodal injection in melanoma patients after resection of their tumor.

In Cohort 2, ECI-006 will be administered 9 times by intranodal injection on top of standard of care anti PD1 in metastatic melanoma patients with stable disease after 3 to 12 months treatment.

ECI-006 activates key immunologically active cells to direct the immune system against the cancer. Expected potential risks for ECI-006 are non-serious and related to the local administration of the product. Hence, the therapy suggested here has the promise to offer considerable benefit to patients without any major risk.


Condition or disease Intervention/treatment Phase
Melanoma Biological: ECI-006 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: • Drug: ECI-006 mRNA Cohort 1: 5 intranodal injections of either 600 µg or 1800 µg mRNA Cohort 2: 9 intranodal injections of either 1800 µg or 3600 µg mRNA
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study to Assess the Safety and Tolerability of ECI-006 mRNA Immunotherapy by Intranodal Administration in Melanoma: (1) Following Surgical Resection, and (2) in Patients With Stable Disease After Standard of Care Immunotherapy Treatment
Actual Study Start Date : June 27, 2017
Actual Primary Completion Date : December 31, 2020
Actual Study Completion Date : January 29, 2021

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Cohort 1 600 µg ECI-006
Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 600 µg ECI-006
Biological: ECI-006
ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules

Experimental: Cohort 1 1800 µg ECI-006
Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 1800 µg ECI-006
Biological: ECI-006
ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules

Experimental: Cohort 2 1800 µg ECI-006
Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 1800 µg ECI-006
Biological: ECI-006
ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules

Experimental: Cohort 2 3600 µg ECI-006
Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 3600 µg ECI-006
Biological: ECI-006
ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules




Primary Outcome Measures :
  1. Incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 [ Time Frame: 24 weeks ]
    Types of toxicities, incidences and severity will be summarized by descriptive statistics


Secondary Outcome Measures :
  1. Immune response associated with ECI-006 administration [ Time Frame: 24 weeks ]
    Antigen-specific T cell responses will be investigated at several time points



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main inclusion criteria Cohort 1:

  1. Age greater than or equal to 18 years and less than or equal to 80 years.
  2. Patients must have histologically proven primary malignant melanoma of skin which has been surgically removed (see exclusion criterion on patients with primary uveal melanoma or melanoma of the mucosae).
  3. Patients with American Joint Committee on Cancer (AJCC) Stage IIc, III or IV.
  4. Patients must have no evidence of disease as evidenced by a whole body 18F fluorodeoxyglucose (FDG) positron emission tomography [PET]/computed tomography [CT] scan to be done at maximum 2 weeks before Visit 2. To exclude the presence of tumor lesions in the brain magnetic resonance imaging (MRI) may be performed.
  5. Full recovery from all prior therapies. A maximum period of 12 weeks following major surgery, or any other major invasive procedure is allowed before start of the study medication; at least 4 weeks should be between major surgery and the start of the immunotherapy
  6. Female patients of childbearing potential should have a negative serum pregnancy test at Visit 1 (Screening) and should use an efficient method of birth control from screening until the first menses after a 4 week period after the last dose of study medication.

Main exclusion criteria Cohort 1:

  1. Patients with primary uveal or mucosal melanoma.
  2. Patients who have received prior systemic therapy and/or active immunotherapy for melanoma, such as antigen loaded dendritic cells or chimeric antigen receptor (CAR) T cells, are excluded. Systemic adjuvant treatment for melanoma that is more than 5 years ago and prior local treatment of primary and metastatic tumor lesions (e.g., surgical resection, isolated limb perfusion radiotherapy) are allowed.
  3. Patients with a history of autoimmune disease such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, rheumatoid arthritis or multiple sclerosis. Vitiligo is not an exclusion criterion
  4. Patients with serious intercurrent chronic or acute illness such as pulmonary [asthma or chronic obstructive pulmonary disease (COPD)] or cardiac (New York Heart Association [NYHA] class III or IV) or hepatic disease or other illness considered by the investigator to constitute an unwarranted high risk for investigational drug treatment.
  5. Concurrent second malignancy other than non-melanoma skin cancer, or controlled superficial bladder cancer. In the event of prior malignancies treated surgically, the patient must be considered NED (no evidence of disease) for a minimum of 3 years prior to enrolment.
  6. Patients on steroid therapy > 10 mg prednisone (or equivalent) or other immunosuppressive agents such as azathioprine or cyclosporine A (but not limited to these) are excluded on the basis of potential immune suppression. Patients must have had 8 weeks of discontinuation of any steroid therapy exceeding > 10 mg prednisone (or equivalent) before first dose.

Main inclusion criteria Cohort 2:

  1. Histologically confirmed AJCC Stage III or Stage IV unresectable disease.
  2. Patient must be free of progression and have stable disease after at least 3 months but less than 12 months of first-line immunotherapy (pembrolizumab, nivolumab or combination of nivolumab and ipilimumab). Patients with clinically stable disease can be either:

    1. Patients with stable disease as defined by RECIST1.1 criteria as assessed on 2 consecutive imagings, or
    2. Patients deemed unlikely to respond further to the standard of care immunotherapy by the investigator, after an initial partial response.
  3. Patient must continue with standard of care pembrolizumab or nivolumab during the study.
  4. Measurable disease by means of clinical examination, computed tomography (CT) or magnetic resonance imaging (MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, defined as:

    • At least 1 tumor lesion that can be accurately and serially measured in at least 1 dimension, and for which the greatest diameter is ≥ 10 mm or at least one malignant lymph node for which the short axis is ≥ 15 mm as measured by contrast enhanced or spiral CT scan and/or
    • At least 1 superficial cutaneous melanoma lesion ≥ 10 mm as measured by calipers and/or
    • At least 1 subcutaneous melanoma ≥ 10 mm lesion and/or
    • Multiple superficial melanoma lesions which in aggregate have a total diameter of ≥ 10 mm

Main exclusion criteria Cohort 2:

  1. Patient who received radiotherapy within 4 weeks prior to the start of treatment with study medication.
  2. Patients with active brain metastases. Patients with brain metastases are eligible if the brain metastases are deemed stable and if the patient is eligible to receive pembrolizumab as standard of care to treat his melanoma in the judgement of the investigator. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 8 weeks prior to study drug administration.
  3. Patients with primary uveal or mucosal melanoma.
  4. Patients that are deemed at risk for autoimmune flare up (e.g. patients that had an ongoing/recurrent irAE in the last 3 months), as determined by the investigator.
  5. Patients who have received prior treatment for advanced melanoma other than standard of care first-line immunotherapy (pembrolizumab, nivolumab or nivolumab/ipilimumab combination) and targeted therapy (encorafenib, dabrafenib and trametinib) for BRAF positive patients preceding standard of care immunotherapy..

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03394937


Locations
Layout table for location information
Belgium
032-004_GZA Sint-Augustinus
Antwerpen, Belgium
032-002_UCL Brussels
Brussel, Belgium
032-003_AZ Maria Middelares
Gent, Belgium
032-001_University Hospital Brussel
Jette, Belgium
Site 032-007_AZ Sint Maarten
Mechelen, Belgium
Spain
034-001_Hospital Clinic de Barcelona
Barcelona, Spain
034-002_MD Anderson Cancer Center
Madrid, Spain
034-003_Hospital Universitario Ramon y Cajal
Madrid, Spain
034-004_Clinica Universidad de Navarra
Pamplona, Spain
Sponsors and Collaborators
eTheRNA immunotherapies
Layout table for additonal information
Responsible Party: eTheRNA immunotherapies
ClinicalTrials.gov Identifier: NCT03394937    
Other Study ID Numbers: E011-MEL
First Posted: January 9, 2018    Key Record Dates
Last Update Posted: June 21, 2021
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas